Abstracts tagged "macrophage activation syndrome and tocilizumab"

Abstract Number: 2325 • 2017 ACR/ARHP Annual Meeting
Extensive Serum Cytokine Analysis in Patients with Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis
Mao Mizuta¹, Masaki Shimizu¹, Natsumi Inoue¹, Kazuko Kasai², Yasuo Nakagishi³ and Akihiro Yachie⁴, ¹Department of Pediatrics, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan, ²Department of Pediatric Rheumatology, Hyogo Prefectural Kobe Children’s Hospital, kobe, Japan, ³Department of Pediatric Rheumatology, Hyogo Prefectural Kobe Children’s Hospital, Kobe, Japan, ⁴Department of Pediatrics, Graduate School of Medical Sciences, Kanazawa University,, Kanazawa, Japan
Background/Purpose: The pathogenesis of Macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (s-JIA) is still unknown, but overproduction of proinflammatory cytokines from activated T…
Abstract Number: 274 • 2013 ACR/ARHP Annual Meeting
Reported Macrophage Activation Syndrome In Patients With Systemic-Onset Juvenile Idiopathic Arthritis Treated With Tocilizumab
Shumpei Yokota^1,2, Yasuhiko Itoh^2,3, Tomohiro Morio^2,4, Naokata Sumitomo^2,5 and Seiji Minota^2,6, ¹Department of Pediatrics, Yokohama City University School of Medicine, Yokohama, Japan, ²The Safety Evaluation Committee of Actemra® for JIA, Tokyo, Japan, ³pediatrics, Nippon Medical School, Tokyo, Japan, ⁴Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan, ⁵pediatrics, Nihon University School of Medicine, tokyo, Japan, ⁶Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke,Tochigi, Japan
Background/Purpose: Systemic-onset juvenile idiopathic arthritis (s-JIA) is a subtype of chronic childhood arthritis that is characterized by a spiking fever, rash, and arthritis. About 7%…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].